NCT05795400Completed
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy: a Pilot Study
Source: ClinicalTrials.gov · Last updated 24 Apr 2026
Brief summary (registry, in English)
Efficacy and safety of early administration of the SGLT-2 inhibitor dapagliflozin will be evaluated in patients with HF, regardless of LVEF, due to amyloid cardiomyopathy.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 20 Jan 2023
- Start date
- 1 Jun 2022
- Primary completion date
- 30 May 2025
- Lead sponsor
- National Medical Research Center for Cardiology, Ministry of Health of Russian Federation
- Diseases
- Amyloidosis, Heart failure
- NCT number
- NCT05795400
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 1 Jun 2022 to the primary completion date, 30 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Administration of disease-modifying treatment of amyloidosis.
Other
- The inability to continue all the activities planned in this study by the patient.
- The onset of pregnancy.
- Patient's voluntary withdrawal of consent to participate in a clinical trial at any point during the conduct of the study.
- Development of intolerable side effects.
Who the study is looking for
- Males and females between 18 and 80 years of age
- HF, confirmed with the increased level of NT-proBNP\>300 pg/mL or BNP\>100 pg/mL
- Transthyretin amyloid cardiomyopathy, confirmed with echocardiography and/or contrast-enhanced cardiac MRI
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| National Medical Research Center for Cardiology, Ministry of Health of Russian Federation Coordinator of this site? Confirm its status | Moscow | Russia | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.